Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

Link, Bettina
Haschke, Manuel
Grignaschi, Nathalie
Bodmer, Michael
Aschmann, Yvonne Zysset
Wenk, Markus
Krähenbühl, Stephan

January 2008

AIMS: To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suit...

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19

Smeets, Tim J.L.
Valkenburg, Abraham J.
van der Jagt, Mathieu
Koch, Birgit C.P.
Endeman, Henrik
Gommers, Diederik A.M.P.J.
Sassen, Sebastian D.T.
Hunfeld, Nicole G.M.

July 2022

Background and Objective: Many patients treated for COVID-19 related acute respiratory distress synd...

Defining the use of midazolam as a probe of CYP3A4 activity: sensitive quantitation of the metabolites and characterization of mechanism-based inactivation

Podoll, Terry D

January 1996

Thesis (Ph. D.)--University of Washington, 1996A highly sensitive GC NCI/MS assay was developed for ...

ROGERS ET AL1’-HYDROXYMIDAZOLAM DOES NOT PREDICT CLEARANCEDRUG ME ABOLISM DRUG METABOLISM Single Plasma Concentrations of 1’-Hydroxymidazolam or the Ratio of 1’-Hydroxymidazolam:Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

Janyce F. Rogers
Anne N. Nafziger
Angela D. M. Kashuba
Daniel S. Streetman
Mario L. Rocci
Edna F. Choo
Grant R. Wilkinson
Joseph S. Bertino

September 2016

Cytochrome P450 (CYP) phenotyping describes ac-tual drug-metabolizing enzyme activity at any point i...

Limited Sampling Strategy of Partial Area Under the Concentration–Time Curves to Estimate Midazolam Systemic Clearance for Cytochrome P450 3A Phenotyping

Masters, Joanna C
Harano, Denise M
Greenberg, Howard E
Tsunoda, Shirley M
Jang, In-Jin
D., Joseph

February 2015

ObjectiveIntravenous (IV) midazolam is the preferred cytochrome P450 (CYP) 3A probe for phenotyping,...

Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

Kim, Jooran S.
Nafziger, Anne N.
Tsunoda, Shirley M.
Choo, Edna F.
Streetman, Daniel S.
Kashuba, Angela D. M.
Kulawy, Robert W.
Beck, Debra J.
Rocci, Mario L.
Wilkinson, Grant R.
Greenblatt, David J.
Bertino, Joseph S.

April 2002

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/97211/1/00912700222011418.pd

Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?

Franken, L.G.W. (Linda)
Masman, A.D. (Anniek)
Winter, B.C.M. (Brenda) de
Baar, F.P.M. (Frans)
Tibboel, D. (Dick)
Gelder, T. (Teun) van
Koch, B.C.P. (Birgit)
Mathot, R.A. (Ron)

January 2017

Aims: Midazolam is the drug of choice for palliative sedation and is titrated to achieve the desired...

Simultaneous determination of midazolam and 1’-hydroxymidazolam in rat plasma by protein precipitation and LC-MS: application to pharmacokinetic study

Chen, Xiaole
Xu, Tao
Wang, Zhe
Pan, Peipei
Luo, Shunbing
Lin, Dan
Hu, Guoxin
Pan, Jianchun

August 2012

A sensitive and selective liquid chromatography–mass spectrometry (LC–MS) method for determination o...

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

Eap, C.B.
Buclin, T.
Cucchia, G.
Zullino, D.
Hustert, E.
Bleiber, G.
Golay, K.P.
Aubert, A.C.
Baumann, P.
Telenti, A.
Kerb, R.

January 2004

OBJECTIVE: We investigated whether the oral administration of a low dose (75 micro g) of midazolam, ...

Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects

Woolsey, Sarah J.
Beaton, Melanie D.
Choi, Yun Hee
Dresser, George K.
Gryn, Steven E.
Kim, Richard B.
Tirona, Rommel G.

April 2016

Due to high basal interindividual variation in cytochrome P450 3A (CYP3A) activity and susceptibilit...

Oral administration of a low dose of midazolam (75μg) as an in vivo probe for CYP3A activity

Eap, Chin
Buclin, Thierry
Cucchia, Gianni
Zullino, Daniele
Hustert, Elisabeth
Bleiber, Gabriela
Golay, Kerry
Aubert, Anne-Catherine
Baumann, Pierre
Telenti, Amalio
Kerb, Reinhold

June 2018

Objective: We investigated whether the oral administration of a low dose (75µg) of midazolam, a CYP3...

Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity

Chen, Ya Chi
Gotzkowsky, S. Karl
Nafziger, Anne N.
Kulawy, Robert W.
Rocci Jr., Mario L.
Bertino Jr., Joseph S.
Kashuba, Angela D.M.

January 2006

A non-invasive proposed method for measuring CYP3A activity is the urinary 6β-hydroxycortisol:cortis...

Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure

Brussee, J.M. (Janneke)
Vet, N.J. (Nienke)
Krekels, E.H.J. (Elke)
Valkenburg, A.J. (Abraham)
Jacqz-Aigrain, E.
Gerven, J. (Joop) van
Swart, E.L. (Eleonore)
van den Anker, J.N. (Johannes N.)
Tibboel, D. (Dick)
Hoog, M. (Matthijs) de
Wildt, S.N. (Saskia) de
Knibbe, C.A.J. (Catherijne)

January 2017

Aims: Inflammation and organ failure have been reported to have an impact on cytochrome P450 (CYP) 3...

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

Eap, C.B.
Buclin, T.
Hustert, E.
Bleiber, G.
Golay, K.P.
Aubert, A.C.
Baumann, P.
Telenti, A.
Kerb, R.

January 2004

OBJECTIVE: We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, coul...

The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?

Magliocco, G.
Desmeules, J.
Bosilkovska, M.
Thomas, A.
Daali, Y.

February 2021

In this study, we assessed the potential use of the 1β-hydroxy-deoxycholic acid (1β-OH-DCA) to deoxy...

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

Link, Bettina
Haschke, Manuel
Grignaschi, Nathalie
Bodmer, Michael
Aschmann, Yvonne Zysset
Wenk, Markus
Krähenbühl, Stephan

January 2008

AIMS: To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suit...

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19

Smeets, Tim J.L.
Valkenburg, Abraham J.
van der Jagt, Mathieu
Koch, Birgit C.P.
Endeman, Henrik
Gommers, Diederik A.M.P.J.
Sassen, Sebastian D.T.
Hunfeld, Nicole G.M.

July 2022

Background and Objective: Many patients treated for COVID-19 related acute respiratory distress synd...

Defining the use of midazolam as a probe of CYP3A4 activity: sensitive quantitation of the metabolites and characterization of mechanism-based inactivation

Podoll, Terry D

January 1996

Thesis (Ph. D.)--University of Washington, 1996A highly sensitive GC NCI/MS assay was developed for ...

ROGERS ET AL1’-HYDROXYMIDAZOLAM DOES NOT PREDICT CLEARANCEDRUG ME ABOLISM DRUG METABOLISM Single Plasma Concentrations of 1’-Hydroxymidazolam or the Ratio of 1’-Hydroxymidazolam:Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

Janyce F. Rogers
Anne N. Nafziger
Angela D. M. Kashuba
Daniel S. Streetman
Mario L. Rocci
Edna F. Choo
Grant R. Wilkinson
Joseph S. Bertino

September 2016

Cytochrome P450 (CYP) phenotyping describes ac-tual drug-metabolizing enzyme activity at any point i...

Limited Sampling Strategy of Partial Area Under the Concentration–Time Curves to Estimate Midazolam Systemic Clearance for Cytochrome P450 3A Phenotyping

Masters, Joanna C
Harano, Denise M
Greenberg, Howard E
Tsunoda, Shirley M
Jang, In-Jin
D., Joseph

February 2015

ObjectiveIntravenous (IV) midazolam is the preferred cytochrome P450 (CYP) 3A probe for phenotyping,...

Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques

Kim, Jooran S.
Nafziger, Anne N.
Tsunoda, Shirley M.
Choo, Edna F.
Streetman, Daniel S.
Kashuba, Angela D. M.
Kulawy, Robert W.
Beck, Debra J.
Rocci, Mario L.
Wilkinson, Grant R.
Greenblatt, David J.
Bertino, Joseph S.

April 2002

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/97211/1/00912700222011418.pd

Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?

Franken, L.G.W. (Linda)
Masman, A.D. (Anniek)
Winter, B.C.M. (Brenda) de
Baar, F.P.M. (Frans)
Tibboel, D. (Dick)
Gelder, T. (Teun) van
Koch, B.C.P. (Birgit)
Mathot, R.A. (Ron)

January 2017

Aims: Midazolam is the drug of choice for palliative sedation and is titrated to achieve the desired...

Simultaneous determination of midazolam and 1’-hydroxymidazolam in rat plasma by protein precipitation and LC-MS: application to pharmacokinetic study

Chen, Xiaole
Xu, Tao
Wang, Zhe
Pan, Peipei
Luo, Shunbing
Lin, Dan
Hu, Guoxin
Pan, Jianchun

August 2012

A sensitive and selective liquid chromatography–mass spectrometry (LC–MS) method for determination o...

Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity.

Eap, C.B.
Buclin, T.
Cucchia, G.
Zullino, D.
Hustert, E.
Bleiber, G.
Golay, K.P.
Aubert, A.C.
Baumann, P.
Telenti, A.
Kerb, R.

January 2004

OBJECTIVE: We investigated whether the oral administration of a low dose (75 micro g) of midazolam, ...

Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single-Time-Point Oral Midazolam Microdose Phenotype in Healthy Subjects

Woolsey, Sarah J.
Beaton, Melanie D.
Choi, Yun Hee
Dresser, George K.
Gryn, Steven E.
Kim, Richard B.
Tirona, Rommel G.

April 2016

Due to high basal interindividual variation in cytochrome P450 3A (CYP3A) activity and susceptibilit...

Oral administration of a low dose of midazolam (75μg) as an in vivo probe for CYP3A activity

Eap, Chin
Buclin, Thierry
Cucchia, Gianni
Zullino, Daniele
Hustert, Elisabeth
Bleiber, Gabriela
Golay, Kerry
Aubert, Anne-Catherine
Baumann, Pierre
Telenti, Amalio
Kerb, Reinhold

June 2018

Objective: We investigated whether the oral administration of a low dose (75µg) of midazolam, a CYP3...

Poor correlation between 6β-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity

Chen, Ya Chi
Gotzkowsky, S. Karl
Nafziger, Anne N.
Kulawy, Robert W.
Rocci Jr., Mario L.
Bertino Jr., Joseph S.
Kashuba, Angela D.M.

January 2006

A non-invasive proposed method for measuring CYP3A activity is the urinary 6β-hydroxycortisol:cortis...

Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure

Brussee, J.M. (Janneke)
Vet, N.J. (Nienke)
Krekels, E.H.J. (Elke)
Valkenburg, A.J. (Abraham)
Jacqz-Aigrain, E.
Gerven, J. (Joop) van
Swart, E.L. (Eleonore)
van den Anker, J.N. (Johannes N.)
Tibboel, D. (Dick)
Hoog, M. (Matthijs) de
Wildt, S.N. (Saskia) de
Knibbe, C.A.J. (Catherijne)

January 2017

Aims: Inflammation and organ failure have been reported to have an impact on cytochrome P450 (CYP) 3...

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects

Eap, C.B.
Buclin, T.
Hustert, E.
Bleiber, G.
Golay, K.P.
Aubert, A.C.
Baumann, P.
Telenti, A.
Kerb, R.

January 2004

OBJECTIVE: We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, coul...

The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker?

Magliocco, G.
Desmeules, J.
Bosilkovska, M.
Thomas, A.
Daali, Y.

February 2021

In this study, we assessed the potential use of the 1β-hydroxy-deoxycholic acid (1β-OH-DCA) to deoxy...

Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

Link, Bettina
Haschke, Manuel
Grignaschi, Nathalie
Bodmer, Michael
Aschmann, Yvonne Zysset
Wenk, Markus
Krähenbühl, Stephan

January 2008

AIMS: To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suit...

Hyperinflammation Reduces Midazolam Metabolism in Critically Ill Adults with COVID-19

Smeets, Tim J.L.
Valkenburg, Abraham J.
van der Jagt, Mathieu
Koch, Birgit C.P.
Endeman, Henrik
Gommers, Diederik A.M.P.J.
Sassen, Sebastian D.T.
Hunfeld, Nicole G.M.

July 2022

Background and Objective: Many patients treated for COVID-19 related acute respiratory distress synd...

Defining the use of midazolam as a probe of CYP3A4 activity: sensitive quantitation of the metabolites and characterization of mechanism-based inactivation

Podoll, Terry D

January 1996

Thesis (Ph. D.)--University of Washington, 1996A highly sensitive GC NCI/MS assay was developed for ...

Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

Abstract

Extracted data

Single Plasma Concentrations of 1′‐Hydroxymidazolam or the Ratio of 1′‐Hydroxymidazolam: Midazolam Do Not Predict Midazolam Clearance in Healthy Subjects

Abstract

Extracted data

Related items

Related items